Date | Price Target | Rating | Analyst |
---|---|---|---|
12/14/2023 | $47.50 | Overweight | Morgan Stanley |
8/10/2023 | $70.00 | Overweight | Cantor Fitzgerald |
3/2/2022 | $194.00 → $102.00 | Outperform | SVB Leerink |
1/21/2022 | $64.00 | Outperform | Macquarie |
12/15/2021 | $189.00 → $136.00 | Overweight | JP Morgan |
11/11/2021 | $222.00 → $217.00 | Buy | Citigroup |
11/10/2021 | $200.00 → $194.00 | Outperform | SVB Leerink |
10/12/2021 | Market Perform | Bernstein |
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)
SC 13G - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)
Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50
Cantor Fitzgerald initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $70.00
SVB Leerink reiterated coverage of Zai Lab with a rating of Outperform and set a new price target of $102.00 from $194.00 previously
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
144 - Zai Lab Ltd (0001704292) (Subject)
10-Q - Zai Lab Ltd (0001704292) (Filer)
8-K - Zai Lab Ltd (0001704292) (Filer)
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study
Manuscript represents the first publication from China's gynecology oncology field to be published in CellPublication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs itData suggest combination of niraparib and ZL-1218, an investigational CCR8 antibody, may decrease tumor burden, offering synergistic potential for improving efficacy in treatment of HRD tumorsZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))))) today announced that data published in the journal Celldemonstrate that neoadjuvant monotherapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib results in a high response rate and reshap
JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $43 to $38.
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt
SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog
– Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth; 47% y-o-y growth at constant exchange rate (CER) – VYVGART® (efgartigimod alfa injection) sales of $23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million – Expansion of Zai Lab's global oncology pipeline with a next generation ROR1 antibody-drug conjugate (ADC) program – Three product approvals in China including XACDURO® for HABP/VABP, efgartigimod SC for gMG, and AUGTYRO™ for ROS1+ NSCLC; expect at least four regulatory submissions to the NMPA within next 12 months including KarXT for schizophrenia – Strong balance sheet w
Company to Host Conference Call and Webcast on August 7, 2024, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that it will report financial results for the second quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, August 6, 2024. The Company will host a live conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registrati
Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) VYVGART® (efgartigimod alfa injection) sales of $13.2 million for the first quarter of 2024, driven by increased patient access; an estimated 2,700 new patients were treated with VYVGART in the first quarter of 2024 Regulatory reviews ongoing for sulbactam-durlobactam for ABC, efgartigimod SC for gMG, and repotrectinib for ROS1+ NSCLC; sBLA submitted for efgartigimod SC in CIDP Strong balance sheet with a cash position1 of $750.8 million as of March 31, 2024, compared to $806.5 million as of December 31, 2023 Company to host confere
Poster session will highlight potential of ZL-1218 to modulate tumor microenvironment and regulate anticancer immune response in advanced solid tumors Trial update demonstrates the advancement of company's robust, internal global oncology pipeline Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that data from a Phase 1 study of ZL-1218, the company's anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escalation clinical trial (NCT05859464) will highlight the potential of ZL-1218 to reduce regulatory T
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that members of the Company's senior management team will participate in the following investor conferences in September 2024: Morgan Stanley 22nd Annual Global Healthcare Conference Location: New York, New York Cantor Fitzgerald Global Healthcare Conference Fireside Chat: Thursday, September 19, 2024, 8:00 a.m. ET in Track 2 Location: New York, New York About Zai Lab Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical con
– Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth; 47% y-o-y growth at constant exchange rate (CER) – VYVGART® (efgartigimod alfa injection) sales of $23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million – Expansion of Zai Lab's global oncology pipeline with a next generation ROR1 antibody-drug conjugate (ADC) program – Three product approvals in China including XACDURO® for HABP/VABP, efgartigimod SC for gMG, and AUGTYRO™ for ROS1+ NSCLC; expect at least four regulatory submissions to the NMPA within next 12 months including KarXT for schizophrenia – Strong balance sheet w
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)